Hikma Pharmaceuticals
Hikma Pharmaceuticals PLC, commonly known as Hikma, is a leading global pharmaceutical company headquartered in the United Kingdom. Founded in 1978, Hikma has established a strong presence in key operational regions, including the Middle East, North Africa, and the United States. The company operates primarily in the generic and branded pharmaceuticals sectors, focusing on injectable medications, oral solids, and complex generics. Hikma is renowned for its commitment to quality and innovation, offering a diverse portfolio of products that cater to various therapeutic areas, including oncology, pain management, and infectious diseases. With a robust market position, Hikma has achieved significant milestones, including numerous FDA approvals and a growing pipeline of new therapies. The company's dedication to improving patient outcomes and expanding access to essential medicines underscores its reputation as a trusted leader in the pharmaceutical industry.
DitchCarbon Score
How does Hikma Pharmaceuticals's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Hikma Pharmaceuticals's score of 64 is higher than 80% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Hikma Pharmaceuticals's reported carbon emissions
In 2024, Hikma Pharmaceuticals reported total greenhouse gas emissions of approximately 1,000,000,000 kg CO2e, comprising 37,625,000 kg CO2e from Scope 1, 85,682,000 kg CO2e from Scope 2, and a significant 860,710,000 kg CO2e from Scope 3 emissions. This represents a comprehensive approach to emissions reporting, covering all relevant scopes. Hikma has set an ambitious target to reduce its Scope 1 and 2 greenhouse gas emissions by 25% by 2030, using a 2020 baseline. This commitment reflects their proactive stance on climate action, aiming for substantial reductions in their operational carbon footprint. Notably, since 2017, the company has achieved a 4% reduction in reported GHG emissions from direct fuel usage and electricity consumption. The company is also committed to achieving net zero emissions by 2050, further underscoring its long-term sustainability goals. This commitment aligns with industry standards and reflects a growing trend among pharmaceutical companies to enhance their environmental responsibility. Overall, Hikma Pharmaceuticals is actively working towards significant emissions reductions while maintaining transparency in its reporting practices, positioning itself as a responsible player in the pharmaceutical industry.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2013 | 2014 | 2015 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Scope 1 | 16,817,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 2 | 49,779,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 3 | - | - | - | - | - | - | - | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Hikma Pharmaceuticals is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
